Abstract: Translation of multipotent mesenchymal stromal cell (MSC)-based therapies is advancing in human and veterinary medicine. One critical issue is the culture of MSC before clinical use. Using fetal bovine serum (FBS) as supplement to the basal medium is still the gold standard for cultivation of many cell types including equine MSC. Alternatives are being explored, with substantial success using platelet lysate-supplemented media for human MSC. However, progress lags behind in the veterinary field. The aim of this study was to establish a scalable protocol for equine platelet lysate (ePL) production and to test the ePL in equine MSC culture. Whole blood was harvested into blood collection bags from 20 healthy horses. After checking sample materials for pathogen contamination, samples from 19 animals were included. Platelet concentrates were prepared using a buffy coat method. Platelets, platelet-derived growth factor BB, and transforming growth factor β1 concentrations were increased in the concentrates compared with whole blood or serum ( < 0.05), while white blood cells were reduced ( < 0.05). The concentrates were lysed using freeze/thaw cycles, which eliminated the cells while growth factor concentrations were maintained. Donor age negatively correlated with platelet and growth factor concentrations after processing ( < 0.05). Finally, all lysates were pooled and the ePL was evaluated as culture medium supplement in comparison with FBS, using adipose-derived MSC from four unrelated donor horses. MSC proliferated well in 10% FBS as well as in 10% ePL. However, using 5 or 2.5% ePL entailed highly inconsistent proliferation or loss of proliferation, with significant differences in generation times and confluencies ( < 0.05). MSC expressed the surface antigens CD90, CD44, and CD29, but CD73 and CD105 detection was low in all culture media. Adipogenic and osteogenic differentiation led to similar results in MSC from different culture media. The buffy coat method is useful to produce equine platelet concentrate with increased platelet and reduced white blood cell content in large scales. The ePL obtained supports MSC expansion similar as FBS when used at the same concentration (10%). Further investigations into equine MSC functionality in culture with ePL should follow.
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The study focuses on developing a scalable production process of equine Platelet Lysate (ePL) and testing its efficiency in the culture of equine Multipotent Mesenchymal Stromal Cells (MSC). The aim is to provide an effective alternative to the current widely-used Fetal Bovine Serum (FBS) for the cultivation of equine MSC.
Collection and Preparation of Samples
Blood samples were collected from 20 healthy horses, and upon testing for pathogen contamination, 19 were included in the study.
Growth factors and platelets were collected from these samples after being concentrated using a buffy coat method.
This method also managed to reduce the content of white blood cells in the samples.
The concentrated platelets were then lysed through freeze/thaw cycles, eliminating the cells but maintaining the growth factor concentrations.
A negative correlation was observed between donor age and concentrations of platelets and growth factors.
Testing of Equine Platelet Lysate in MSC Culture
All lysates obtained were combined, culminating into the production of an ePL which was then used as a medium supplement in MSC culture, in comparison with FBS.
Adipose-derived MSCs from four unrelated horses were used for this experiment.
MSC proliferated well in both 10% FBS and 10% ePL, demonstrating the effectiveness of ePL as a growth medium.
However, lower concentrations of ePL (5% or 2.5%) led to inconsistent proliferation or complete loss of proliferation. Substantial differences were noted in generation times and confluences.
Analysis of MSC Expression and Differentiation
MSC in all culture media expressed CD90, CD44, and CD29 surface antigens while the detection of CD73 and CD105 was low.
Adipogenic and osteogenic differentiation of the MSC led to similar results irrespective of the culture media used.
Conclusion and Future Research
The buffy coat method showed usefulness in producing horse platelet concentrate which can be used in large-scale production.
This ePL also supports the expansion of MSC similarly to FBS, when used at identical concentrations (of 10%).
The study hence proposes that future research should focus on further researching equine MSC functionality in culture with ePL in an effort to establish ePL as an established alternative to FBS in cultivating equine MSC.
Cite This Article
APA
Hagen A, Lehmann H, Aurich S, Bauer N, Melzer M, Moellerberndt J, Patané V, Schnabel CL, Burk J.
(2021).
Scalable Production of Equine Platelet Lysate for Multipotent Mesenchymal Stromal Cell Culture.
Front Bioeng Biotechnol, 8, 613621.
https://doi.org/10.3389/fbioe.2020.613621
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
This article includes 100 references
Anderson LD, Raub RH, Grieger DM, Morris J, Weber JD. Transforming growth factor-β1 concentrations in equine synovial fluid. J. Equine Vet. Sci. 18, 109–113.
Astori G, Amati E, Bambi F, Bernardi M, Chieregato K, Schäfer R, Sella S, Rodeghiero F. Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future.. Stem Cell Res Ther 2016 Jul 13;7(1):93.
Becherucci V, Piccini L, Casamassima S, Bisin S, Gori V, Gentile F, Ceccantini R, De Rienzo E, Bindi B, Pavan P, Cunial V, Allegro E, Ermini S, Brugnolo F, Astori G, Bambi F. Human platelet lysate in mesenchymal stromal cell expansion according to a GMP grade protocol: a cell factory experience.. Stem Cell Res Ther 2018 May 2;9(1):124.
Ben Azouna N, Jenhani F, Regaya Z, Berraeis L, Ben Othman T, Ducrocq E, Domenech J. Phenotypical and functional characteristics of mesenchymal stem cells from bone marrow: comparison of culture using different media supplemented with human platelet lysate or fetal bovine serum.. Stem Cell Res Ther 2012 Feb 14;3(1):6.
Burnouf T, Goubran HA, Seghatchian J. Multifaceted regenerative lives of expired platelets in the second decade of the 21st century.. Transfus Apher Sci 2014 Oct;51(2):107-12.
Burnouf T, Strunk D, Koh MB, Schallmoser K. Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation?. Biomaterials 2016 Jan;76:371-87.
Cholewa D, Stiehl T, Schellenberg A, Bokermann G, Joussen S, Koch C, Walenda T, Pallua N, Marciniak-Czochra A, Suschek CV, Wagner W. Expansion of adipose mesenchymal stromal cells is affected by human platelet lysate and plating density.. Cell Transplant 2011;20(9):1409-22.
Del Bue M, Riccò S, Conti V, Merli E, Ramoni R, Grolli S. Platelet lysate promotes in vitro proliferation of equine mesenchymal stem cells and tenocytes.. Vet Res Commun 2007 Aug;31 Suppl 1:289-92.
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.. Cytotherapy 2006;8(4):315-7.
Erickson GA, Bolin SR, Landgraf JG. Viral contamination of fetal bovine serum used for tissue culture: risks and concerns.. Dev Biol Stand 1991;75:173-5.
European Committee (Partial Agreement) on Blood Transfusion. Guide to the Preparation, Use and Quality Assurance of Blood Components. Technical Report. Council of Europe.
European Medicines Agency London. Guideline on the Use of Bovine Serum in the Manufacture of Human Biological Medicinal Products. Technical Report EMA/CHMP/BWP/457920/2012 rev 1. Committee for Medicinal Products for Human Use (CHMP). European Medicines Agency.
Faraday N, Scharpf RB, Dodd-o JM, Martinez EA, Rosenfeld BA, Dorman T. Leukocytes can enhance platelet-mediated aggregation and thromboxane release via interaction of P-selectin glycoprotein ligand 1 with P-selectin.. Anesthesiology 2001 Jan;94(1):145-51.
Gilbertie JM, Long JM, Schubert AG, Berglund AK, Schaer TP, Schnabel LV. Pooled Platelet-Rich Plasma Lysate Therapy Increases Synoviocyte Proliferation and Hyaluronic Acid Production While Protecting Chondrocytes From Synoviocyte-Derived Inflammatory Mediators.. Front Vet Sci 2018;5:150.
Gittel C, Brehm W, Burk J, Juelke H, Staszyk C, Ribitsch I. Isolation of equine multipotent mesenchymal stromal cells by enzymatic tissue digestion or explant technique: comparison of cellular properties.. BMC Vet Res 2013 Oct 29;9:221.
Gottipamula S, Sharma A, Krishnamurthy S, Majumdar AS, Seetharam RN. Human platelet lysate is an alternative to fetal bovine serum for large-scale expansion of bone marrow-derived mesenchymal stromal cells.. Biotechnol Lett 2012 Jul;34(7):1367-74.
Grimaud E, Heymann D, Rédini F. Recent advances in TGF-beta effects on chondrocyte metabolism. Potential therapeutic roles of TGF-beta in cartilage disorders.. Cytokine Growth Factor Rev 2002 Jun;13(3):241-57.
Grogan SP, Barbero A, Winkelmann V, Rieser F, Fitzsimmons JS, O'Driscoll S, Martin I, Mainil-Varlet P. Visual histological grading system for the evaluation of in vitro-generated neocartilage.. Tissue Eng 2006 Aug;12(8):2141-9.
Gulliksson H. Platelets from platelet-rich-plasma versus buffy-coat-derived platelets: what is the difference?. Rev Bras Hematol Hemoter 2012;34(2):76-7.
Hoareau GL, Jandrey KE, Burges J, Bremer D, Tablin F. Comparison of the platelet-rich plasma and buffy coat protocols for preparation of canine platelet concentrates.. Vet Clin Pathol 2014 Dec;43(4):513-8.
Horn P, Bokermann G, Cholewa D, Bork S, Walenda T, Koch C, Drescher W, Hutschenreuther G, Zenke M, Ho AD, Wagner W. Impact of individual platelet lysates on isolation and growth of human mesenchymal stromal cells.. Cytotherapy 2010 Nov;12(7):888-98.
Jochems CE, van der Valk JB, Stafleu FR, Baumans V. The use of fetal bovine serum: ethical or scientific problem?. Altern Lab Anim 2002 Mar-Apr;30(2):219-27.
Karnieli O, Friedner OM, Allickson JG, Zhang N, Jung S, Fiorentini D, Abraham E, Eaker SS, Yong TK, Chan A, Griffiths S, Wehn AK, Oh S, Karnieli O. A consensus introduction to serum replacements and serum-free media for cellular therapies.. Cytotherapy 2017 Feb;19(2):155-169.
Klatte-Schulz F, Schmidt T, Uckert M, Scheffler S, Kalus U, Rojewski M, Schrezenmeier H, Pruss A, Wildemann B. Comparative Analysis of Different Platelet Lysates and Platelet Rich Preparations to Stimulate Tendon Cell Biology: An In Vitro Study.. Int J Mol Sci 2018 Jan 10;19(1).
Lunn DP, Holmes MA, Antczak DF, Agerwal N, Baker J, Bendali-Ahcene S, Blanchard-Channell M, Byrne KM, Cannizzo K, Davis W, Hamilton MJ, Hannant D, Kondo T, Kydd JH, Monier MC, Moore PF, O'Neil T, Schram BR, Sheoran A, Stott JL, Sugiura T, Vagnoni KE. Report of the Second Equine Leucocyte Antigen Workshop, Squaw valley, California, July 1995.. Vet Immunol Immunopathol 1998 Mar 31;62(2):101-43.
Mishra A, Tummala P, King A, Lee B, Kraus M, Tse V, Jacobs CR. Buffered platelet-rich plasma enhances mesenchymal stem cell proliferation and chondrogenic differentiation.. Tissue Eng Part C Methods 2009 Sep;15(3):431-5.
Mohammadi S, Nikbakht M, Malek Mohammadi A, Zahed Panah M, Ostadali MR, Nasiri H, Ghavamzadeh A. Human Platelet Lysate as a Xeno Free Alternative of Fetal Bovine Serum for the In Vitro Expansion of Human Mesenchymal Stromal Cells.. Int J Hematol Oncol Stem Cell Res 2016 Jul 1;10(3):161-71.
Naskou MC, Sumner S, Berezny A, Copland IB, Peroni JF. Fibrinogen-Depleted Equine Platelet Lysate Affects the Characteristics and Functionality of Mesenchymal Stem Cells.. Stem Cells Dev 2019 Dec 1;28(23):1572-1580.
Prins HJ, Rozemuller H, Vonk-Griffioen S, Verweij VG, Dhert WJ, Slaper-Cortenbach IC, Martens AC. Bone-forming capacity of mesenchymal stromal cells when cultured in the presence of human platelet lysate as substitute for fetal bovine serum.. Tissue Eng Part A 2009 Dec;15(12):3741-51.
Roscher K. Platelets in equids - an underrated biomarker?. DVG Service GmbH. Available online at: http://geb.uni-giessen.de/geb/volltexte/2019/14904/ (accessed October 01, 2020).
Rubio-Azpeitia E, Andia I. Partnership between platelet-rich plasma and mesenchymal stem cells: in vitro experience.. Muscles Ligaments Tendons J 2014 Jan;4(1):52-62.
Schallmoser K, Bartmann C, Rohde E, Reinisch A, Kashofer K, Stadelmeyer E, Drexler C, Lanzer G, Linkesch W, Strunk D. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells.. Transfusion 2007 Aug;47(8):1436-46.
Schallmoser K, Henschler R, Gabriel C, Koh MBC, Burnouf T. Production and Quality Requirements of Human Platelet Lysate: A Position Statement from the Working Party on Cellular Therapies of the International Society of Blood Transfusion.. Trends Biotechnol 2020 Jan;38(1):13-23.
Schallmoser K, Rohde E, Bartmann C, Obenauf AC, Reinisch A, Strunk D. Platelet-derived growth factors for GMP-compliant propagation of mesenchymal stromal cells.. Biomed Mater Eng 2009;19(4-5):271-6.
Shih DT, Chen JC, Chen WY, Kuo YP, Su CY, Burnouf T. Expansion of adipose tissue mesenchymal stromal progenitors in serum-free medium supplemented with virally inactivated allogeneic human platelet lysate.. Transfusion 2011 Apr;51(4):770-8.
Sundin M, Ringdén O, Sundberg B, Nava S, Götherström C, Le Blanc K. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients.. Haematologica 2007 Sep;92(9):1208-15.
Trento C, Bernardo ME, Nagler A, Kuçi S, Bornhäuser M, Köhl U, Strunk D, Galleu A, Sanchez-Guijo F, Gaipa G, Introna M, Bukauskas A, Le Blanc K, Apperley J, Roelofs H, Van Campenhout A, Beguin Y, Kuball J, Lazzari L, Avanzini MA, Fibbe W, Chabannon C, Bonini C, Dazzi F. Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation.. Biol Blood Marrow Transplant 2018 Nov;24(11):2365-2370.
van der Valk J, Brunner D, De Smet K, Fex Svenningsen A, Honegger P, Knudsen LE, Lindl T, Noraberg J, Price A, Scarino ML, Gstraunthaler G. Optimization of chemically defined cell culture media--replacing fetal bovine serum in mammalian in vitro methods.. Toxicol In Vitro 2010 Jun;24(4):1053-63.
van der Valk J, Mellor D, Brands R, Fischer R, Gruber F, Gstraunthaler G, Hellebrekers L, Hyllner J, Jonker FH, Prieto P, Thalen M, Baumans V. The humane collection of fetal bovine serum and possibilities for serum-free cell and tissue culture.. Toxicol In Vitro 2004 Feb;18(1):1-12.
van Kuppeveld FJ, van der Logt JT, Angulo AF, van Zoest MJ, Quint WG, Niesters HG, Galama JM, Melchers WJ. Genus- and species-specific identification of mycoplasmas by 16S rRNA amplification.. Appl Environ Microbiol 1992 Aug;58(8):2606-15.
de Wildt-Eggen J, Schrijver JG, Bins M. WBC content of platelet concentrates prepared by the buffy coat method using different processing procedures and storage solutions.. Transfusion 2001 Nov;41(11):1378-83.
World Health Organization. WHO Guidelines on Tissue Infectivity Distribution in Transmissible Spongiform Encephalopathies. Available online at: https://www.who.int/bloodproducts/cs/TSEPUBLISHEDREPORT.pdf?ua=1 (accessed October 02, 2020).
Zheng X, Baker H, Hancock WS, Fawaz F, McCaman M, Pungor E Jr. Proteomic analysis for the assessment of different lots of fetal bovine serum as a raw material for cell culture. Part IV. Application of proteomics to the manufacture of biological drugs.. Biotechnol Prog 2006 Sep-Oct;22(5):1294-300.
Karimi E, Vahedi N, Sarbandi RR, Parandakh A, Ganjoury C, Sigaroodi F, Najmoddin N, Tabatabaei M, Tafazzoli-Shadpour M, Ardeshirylajimi A, Khani MM. Nanoscale vibration could promote tenogenic differentiation of umbilical cord mesenchymal stem cells. In Vitro Cell Dev Biol Anim 2023 Jun;59(6):401-409.
Heyman E, Meeremans M, Devriendt B, Olenic M, Chiers K, De Schauwer C. Validation of a color deconvolution method to quantify MSC tri-lineage differentiation across species. Front Vet Sci 2022;9:987045.
Pilgrim CR, McCahill KA, Rops JG, Dufour JM, Russell KA, Koch TG. A Review of Fetal Bovine Serum in the Culture of Mesenchymal Stromal Cells and Potential Alternatives for Veterinary Medicine. Front Vet Sci 2022;9:859025.
Burk J, Melzer M, Hagen A, Lips KS, Trinkaus K, Nimptsch A, Leopold J. Phospholipid Profiles for Phenotypic Characterization of Adipose-Derived Multipotent Mesenchymal Stromal Cells. Front Cell Dev Biol 2021;9:784405.
Wanes D, Naim HY, Dengler F. Proliferation and Differentiation of Intestinal Caco-2 Cells Are Maintained in Culture with Human Platelet Lysate Instead of Fetal Calf Serum. Cells 2021 Nov 5;10(11).
Bzinkowska A, Sarnowska A. Assessment of the Dose-Dependent Effect of Human Platelet Lysate on Wharton's Jelly-Derived Mesenchymal Stem/Stromal Cells Culture for Manufacturing Protocols. Stem Cells Cloning 2024;17:21-32.
Moellerberndt J, Niebert S, Fey K, Hagen A, Burk J. Impact of platelet lysate on immunoregulatory characteristics of equine mesenchymal stromal cells. Front Vet Sci 2024;11:1385395.